OrthoPediatrics (NASDAQ:KIDS) Reaches New 1-Year High – Still a Buy?

OrthoPediatrics Corp. (NASDAQ:KIDS)’s stock price hit a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $25.38 and last traded at $25.2860, with a volume of 78942 shares. The stock had previously closed at $24.70.

Analysts Set New Price Targets

A number of research firms have recently issued reports on KIDS. TD Cowen reissued a “buy” rating on shares of OrthoPediatrics in a research report on Monday, June 15th. Weiss Ratings upgraded shares of OrthoPediatrics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, August 5th. BTIG Research lifted their price objective on shares of OrthoPediatrics from $24.00 to $29.00 and gave the company a “buy” rating in a report on Thursday. Needham & Company LLC upped their target price on OrthoPediatrics from $30.00 to $35.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. Finally, Canaccord Genuity Group set a $25.00 price target on OrthoPediatrics in a research report on Friday, April 24th. Nine research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, OrthoPediatrics currently has a consensus rating of “Moderate Buy” and a consensus price target of $26.44.

OrthoPediatrics Trading Up 3.9%

The company has a 50 day moving average of $20.53 and a two-hundred day moving average of $18.29. The stock has a market capitalization of $691.91 million, a PE ratio of -15.77 and a beta of 0.98. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.17 and a current ratio of 4.78.

OrthoPediatrics (NASDAQ:KIDS) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($0.26) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.04. The business had revenue of $70.51 million for the quarter, compared to analyst estimates of $68.21 million. OrthoPediatrics had a negative return on equity of 8.10% and a negative net margin of 15.72%. Sell-side analysts predict that OrthoPediatrics Corp. will post -1.14 EPS for the current year.

Hedge Funds Weigh In On OrthoPediatrics

Several hedge funds have recently made changes to their positions in the company. Russell Investments Group Ltd. grew its stake in OrthoPediatrics by 433.1% during the 3rd quarter. Russell Investments Group Ltd. now owns 1,402 shares of the company’s stock valued at $26,000 after purchasing an additional 1,139 shares during the last quarter. Legal & General Group Plc acquired a new position in OrthoPediatrics in the 2nd quarter worth approximately $34,000. Northwestern Mutual Wealth Management Co. raised its position in OrthoPediatrics by 5,226.5% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 2,610 shares of the company’s stock worth $46,000 after buying an additional 2,561 shares during the last quarter. Caption Management LLC purchased a new stake in shares of OrthoPediatrics in the 3rd quarter valued at $54,000. Finally, BNP Paribas Financial Markets increased its stake in shares of OrthoPediatrics by 60.2% in the third quarter. BNP Paribas Financial Markets now owns 3,288 shares of the company’s stock worth $61,000 after acquiring an additional 1,235 shares during the period. 69.05% of the stock is owned by institutional investors and hedge funds.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.